Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.
Yahoo3 days agoIQV
How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story
Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...
Yahoo7 days agoIQV
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Yahoo7 days agoIQV
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution
Yahoo7 days agoIQV
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo8 days agoIQV
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
Yahoo9 days agoIQV
2 Large-Cap Stocks with Exciting Potential and 1 That Underwhelm
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Yahoo10 days agoIQV
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Yahoo14 days agoIQV
IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish?
Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.
Yahoo14 days agoIQV
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
RESEARCH TRIANGLE PARK, N.C., August 20, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.
Yahoo14 days agoIQV
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
RESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.
Yahoo17 days agoIQV
This Healthcare Services Stock Has 37% Upside
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
Yahoo22 days agoIQV
Amgen Stock And The Price Of A Promise
Management raised its full-year forecast, but the market seems to be asking for more than a higher target.
Yahoo22 days agoIQV
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
Yahoo23 days agoIQV
Rotation Away From Tech Lifts Moat Index In July
The Moat Index gained 3.96%, outperforming the S&P 500 as its lower mega-cap technology exposure and financials tilt paid off.
SeekingAlpha24 days agoIQV
How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook
In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...
Yahoo26 days agoIQV
IQVIA, Medera Partner to Accelerate Development of Cardiac Gene Therapies
By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme
Yahoo29 days agoIQV
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
Yahoo29 days agoIQV
FISV Q2 Earnings Miss Estimates on Margin Pressure, Revenues Decline
Fiserv's Q2 revenues miss estimates and margin pressure leads to an earnings miss and cuts in its 2026 growth and profit outlook.
Yahoo29 days agoIQV